Map Pharmaceuticals (MAPP -2.7%) says it plans to meet with the FDA during the current quarter to discuss manufacturing issues that are hindering the approval of its migraine medication Levadex.
Map Pharmaceuticals (MAPP -2.7%) says it plans to meet with the FDA during the current quarter...
Recommended For You
More Trending News
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MAPP-OLD | - | - |
| MAP Pharmaceuticals, Inc. | ||